Kymab has defeated an opposition by Regeneron against the grant of an Australian patent covering transgenic mouse platforms for antibody discovery on all grounds

Kymab has defeated an opposition by Regeneron against the grant of an Australian patent covering transgenic mouse platforms for antibody discovery on all grounds

Cambridge, UK; 2 September 2019: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, announces that it has received a decision from the Australian Patent Office (IP Australia) rejecting on all grounds an opposition by Regeneron Pharmaceuticals Inc ("Regeneron") against the grant of a Kymab patent covering genetically modified mice containing human-mouse chimeric antibody loci, humanized antibodies from such mice, cell lines for manufacturing antibodies and pharmaceuticals containing antibodies.